SPOTLIGHT -
Dr. Hoffman on the Design of an Ongoing Trial Testing PTG-300 in Polycythemia Vera
Ronald Hoffman, MD, discusses the design of an ongoing phase 2 trial evaluating the first-in-class synthetic hepcidin mimetic PTG-300 in patients with polycythemia vera.
Read More
Dr. Hoffman on the Safety Profile of PTG-300 in Polycythemia Vera
Ronald Hoffman, MD, discusses the safety profile of the first-in-class synthetic hepcidin mimetic agent PTG-300 in patients with polycythemia vera.
Dr. Hoffman on Advantages of Self-Administration With PTG-300 in Polycythemia Vera
Ronald Hoffman, MD, discusses the advantages of self-administration with the investigational hepcidin mimetic PTG-300 for patients with polycythemia vera (PV).
Dr. Hoffman on the Mechanism of Action of PTG-300 in Polycythemia Vera
Ronald Hoffman, MD, discusses the mechanism of action of the investigational hepcidin mimetic PTG-300 in polycythemia vera.
Dr. Hoffman on the Current Polycythemia Vera Treatment Paradigm
Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.
Cabozantinib Plus Nivolumab/Ipilimumab Generates PFS and DCR in Metastatic Soft Tissue Sarcoma
PRT811 Elicits Responses and Shows Safety in Advanced Glioma and Uveal Melanoma
Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer
Frontline Nivolumab/Ipilimumab Plus Chemotherapy Maintains Efficacy Advantage in Metastatic NSCLC
